Lv Dan, Guo Lianying, Zhang Ting, Huang Lin
Department of Pathophysiology, Dalian Medical University, Dalian, Liaoning 116044, P.R. China.
Oncotarget. 2017 Apr 20;8(40):69076-69085. doi: 10.18632/oncotarget.17299. eCollection 2017 Sep 15.
The proline-rich Akt substrate of 40 kDa (PRAS40) is a substrate of Akt and a component of the mammalian target of rapamycin complex 1 (mTORC1). Locating at the crossroad of the PI3K/Akt pathway and the mTOR pathway, PRAS40 is phosphorylated by growth factors or other stimuli, and regulates the activation of these signaling pathways in turn. PRAS40 plays an important role in metabolic disorders and multiple cancers, and the phosphorylation of PRAS40 is often associated with the tumor progression of melanoma, prostate cancer, etc. PRAS40 promotes tumorigenesis by deregulating cellular proliferation, apoptosis, senescence, metastasis, etc. Herein, we provide an overview on current understandings of PRAS40 signaling in the tumor formation and progression, which suggests that PRAS40 or phospho-PRAS40 could become a novel biomarker and therapeutic target in tumor.
富含脯氨酸的40kDa Akt底物(PRAS40)是Akt的底物,也是雷帕霉素复合物1(mTORC1)的哺乳动物靶点的组成部分。PRAS40位于PI3K/Akt途径和mTOR途径的交叉点,被生长因子或其他刺激磷酸化,并依次调节这些信号通路的激活。PRAS40在代谢紊乱和多种癌症中起重要作用,PRAS40的磷酸化常与黑色素瘤、前列腺癌等肿瘤进展相关。PRAS40通过解除对细胞增殖、凋亡、衰老、转移等的调控来促进肿瘤发生。在此,我们概述了目前对PRAS40信号在肿瘤形成和进展中的理解,这表明PRAS40或磷酸化PRAS40可能成为肿瘤中的新型生物标志物和治疗靶点。